A Sober Look At This Psychedelic Stock

Amid growing acceptance of the use of psychedelic drugs for treating mental disorders, the clinical-stage biotech company featured in today’s article, which has a pipeline of seemingly promising treatments based on psychedelic substances, has seen its stock surge 773.9% over the past year. Is the stock a buy – or do potential headwinds make it one to avoid for now? CLICK HERE.